SHOC2 and cancer: Multiple KRAS-mutant cancers were recently shown to be vulnerable to the loss of SHOC2 in the context of MEK inhibition, confirming the link between SHOC2 and MAP kinase pathway-driven cancers (Sulahian et al., 2019).